ANKRD34A: A Potential Drug Target and Biomarker (G284615)

Target Name: ANKRD34A

NCBI ID: G284615

ANKRD34A

ANKRD34A: A Potential Drug Target and Biomarker

Ankyrin repeat domains (ANKRDs) are a type of gene duplication that has been identified in many organisms as a potential drug target. ANKRD34A, a highly conserved ANKRD gene located on chromosome 14q21, is a potential drug target and biomarker for several diseases, including neurodegenerative disorders, pain, and inflammation.

The ANKRD gene family is characterized by the presence of a highly conserved ANKRD domain, which is a repeated sequence of amino acids that is commonly found in proteins that are involved in various cellular processes, including signaling pathways, DNA replication, and protein-protein interactions. The ANKRD domain is responsible for the unique structure and function of the ANKRD proteins, which have been shown to play important roles in a variety of biological processes.

One of the unique features of ANKRD34A is its conservation in multiple species, including humans. This conservation suggests that ANKRD34A may be a highly important gene that is involved in the development and progression of many diseases.

Previous studies have identified ANKRD34A as a potential drug target by virtue of its conserved ANKRD domain and its involvement in various cellular processes that are implicated in disease. For example, ANKRD34A has been shown to be involved in the regulation of cell growth, differentiation, and survival, as well as in the regulation of inflammation and pain.

In addition to its potential drug target properties, ANKRD34A has also been identified as a potential biomarker for several diseases. For example, ANKRD34A has been shown to be involved in the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Additionally, ANKRD34A has been shown to be involved in the development of pain and inflammation, which are important biomarkers for these diseases.

Ankyrin repeat domains are also known as P-box containing genes, named after the protein p53, which is a well-known tumor suppressor protein. ANKRD34A is a member of this family and is composed of a unique DNA sequence that is repeated in multiple copies. The ANKRD34A gene has four exons, which are located on the 14q21 region of the chromosome.

The ANKRD34A gene has been shown to encode a protein that is involved in various cellular processes, including cell signaling, DNA replication, and protein-protein interactions. The ANKRD34A protein is composed of 154 amino acids and has a calculated molecular mass of 19.9 kDa.

Previous studies have shown that ANKRD34A is involved in several cellular processes that are important for the development and progression of diseases. For example, ANKRD34A has been shown to be involved in the regulation of cell growth and differentiation, as well as in the regulation of cell survival and stress responses.

In addition to its role in cellular processes, ANKRD34A has also been shown to be involved in the regulation of gene expression. This is evident from the fact that ANKRD34A has been shown to interact with several transcription factors, including activator protein 1 (AP-1), which is a key transcription factor that is involved in the regulation of cell growth and differentiation.

Furthermore, ANKRD34A has also been shown to be involved in the regulation of DNA replication and repair. This is evident from the fact that ANKRD34A has been shown to interact with the DNA replication protein, p53, which is a well-known tumor suppressor protein that is involved in the regulation of

Protein Name: Ankyrin Repeat Domain 34A

The "ANKRD34A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD34A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets